Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Status Completed

Clinical Trial Summary

This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.

Clinical Trial Description

The rationale for the proposed research is to develop an acute intervention that can improve treatment outcomes in opioid use disorder (OUD) by reducing craving, a primary factor contributing to early relapse. Although liraglutide was approved for human use in 2010, there are no data testing the effectiveness in patients with an OUD. The objective of the proposed research is to test whether treatment with a GLP-1R agonist can reduce craving in humans with OUD. Understanding how a 'satiety' agent may affect craving and brain responses to drug cues in an OUD population would provide entirely novel information. If liraglutide shows a trend towards efficacy, and safety of the GLP-1R agonist is demonstrated in this population, it would provide an indication to run the second phase, multi-center clinical trial of GLP-1R agonist in OUD patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04199728
Study type	Interventional
Source	Milton S. Hershey Medical Center
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	October 18, 2021
Completion date	September 13, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03950492` - Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder	N/A
Completed	`NCT00000335` - Activity Monitoring Assessment of Opiate Withdrawal - 4	Phase 2
Active, not recruiting	`NCT03949764` - The Kentucky Viral Hepatitis Treatment Study	Phase 4
Enrolling by invitation	`NCT06084221` - Fatal Overdose Review Teams - Research to Enhance Surveillance Systems	N/A
Completed	`NCT02978417` - Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings	Phase 4
Withdrawn	`NCT03137030` - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults	Phase 1
Withdrawn	`NCT03137017` - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults	Phase 1
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT00710385` - Abuse Liability of Suboxone Versus Subutex	Phase 3
Completed	`NCT00142935` - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1	N/A
Completed	`NCT00218309` - Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals	Phase 2
Completed	`NCT00067184` - Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
Terminated	`NCT00000243` - Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone	N/A
Completed	`NCT00000264` - Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16	N/A
Completed	`NCT00000257` - Effects of Alcohol History on Effects of Nitrous Oxide - 9	N/A
Completed	`NCT00000306` - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3	Phase 2
Completed	`NCT00000279` - Novel Medications for Opiate Detoxification - 4	Phase 2
Completed	`NCT00000249` - Effects of Subanesthetic Concentrations of Nitrous Oxide - 1	Phase 2
Recruiting	`NCT04933084` - Pre-operative Education Modalities to Decrease Opioid Use	N/A
Recruiting	`NCT03610672` - Mobile Intervention for Young Opioid Users	N/A